AR023398A1 - Terapia para melanomas - Google Patents
Terapia para melanomasInfo
- Publication number
- AR023398A1 AR023398A1 ARP000101574A ARP000101574A AR023398A1 AR 023398 A1 AR023398 A1 AR 023398A1 AR P000101574 A ARP000101574 A AR P000101574A AR P000101574 A ARP000101574 A AR P000101574A AR 023398 A1 AR023398 A1 AR 023398A1
- Authority
- AR
- Argentina
- Prior art keywords
- therapy
- melanomas
- treatment
- well
- alpha
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Se describen métodos para tratar pacientes nuevos al tratamiento, así como también pacientes con experiencia en el tratamiento, que tienen melanoma, paraincrementar el tiempo de supervivencia libre de progresion que involucra la administracion de unacantidad terapéuticamente eficaz de interferon-alfa pegilado,por ejemplo, interferon alfa-2b pegilado, así como también terapia coadyuvante para cirugía definitiva.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28836699A | 1999-04-08 | 1999-04-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR023398A1 true AR023398A1 (es) | 2002-09-04 |
Family
ID=23106795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000101574A AR023398A1 (es) | 1999-04-08 | 2000-04-06 | Terapia para melanomas |
Country Status (22)
Country | Link |
---|---|
EP (3) | EP2025344B1 (es) |
JP (1) | JP2000319195A (es) |
CN (1) | CN1390132A (es) |
AR (1) | AR023398A1 (es) |
AT (3) | ATE419001T1 (es) |
AU (1) | AU771569B2 (es) |
BR (1) | BR0009646A (es) |
CA (1) | CA2303992A1 (es) |
CO (1) | CO5170404A1 (es) |
CY (1) | CY1108922T1 (es) |
DE (3) | DE60045591D1 (es) |
DK (2) | DK1043026T3 (es) |
ES (2) | ES2239954T3 (es) |
HK (2) | HK1032349A1 (es) |
HU (1) | HU230057B1 (es) |
MY (1) | MY126763A (es) |
NO (1) | NO328111B1 (es) |
PE (1) | PE20010027A1 (es) |
PT (2) | PT1535622E (es) |
TW (1) | TWI292320B (es) |
WO (1) | WO2000061175A2 (es) |
ZA (1) | ZA200108173B (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140038382A (ko) | 2011-03-10 | 2014-03-28 | 프로벡투스 파마슈티컬스 인코포레이티드 | 암의 치료 증대를 위한 국소 면역조절 치료제와 전신 면역조절 치료제의 복합제 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
US4492537A (en) | 1982-12-10 | 1985-01-08 | Awerkamp John B | Fluid-operated oil or water well pump |
US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
JP2514950B2 (ja) | 1986-03-10 | 1996-07-10 | エフ・ホフマン―ラ ロシユ アーゲー | 化学修飾蛋白質,その製造法および中間体 |
US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
AU691225B2 (en) | 1993-11-10 | 1998-05-14 | Schering Corporation | Improved interferon polymer conjugates |
US5766582A (en) | 1994-10-11 | 1998-06-16 | Schering Corporation | Stable, aqueous alfa interferon solution formulations |
JP2758154B2 (ja) | 1995-04-06 | 1998-05-28 | エフ・ホフマン−ラ ロシユ アーゲー | インターフェロンを含む液体製剤 |
US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
TW517067B (en) | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
-
2000
- 2000-04-06 TW TW089106309A patent/TWI292320B/zh not_active IP Right Cessation
- 2000-04-06 AT AT05002951T patent/ATE419001T1/de active
- 2000-04-06 AR ARP000101574A patent/AR023398A1/es unknown
- 2000-04-06 ES ES00107101T patent/ES2239954T3/es not_active Expired - Lifetime
- 2000-04-06 EP EP08020311A patent/EP2025344B1/en not_active Expired - Lifetime
- 2000-04-06 HU HU0200775A patent/HU230057B1/hu not_active IP Right Cessation
- 2000-04-06 PE PE2000000310A patent/PE20010027A1/es not_active Application Discontinuation
- 2000-04-06 ES ES05002951T patent/ES2319776T3/es not_active Expired - Lifetime
- 2000-04-06 CA CA002303992A patent/CA2303992A1/en not_active Abandoned
- 2000-04-06 EP EP05002951A patent/EP1535622B1/en not_active Expired - Lifetime
- 2000-04-06 DE DE60045591T patent/DE60045591D1/de not_active Expired - Lifetime
- 2000-04-06 AU AU42046/00A patent/AU771569B2/en not_active Ceased
- 2000-04-06 AT AT08020311T patent/ATE496631T1/de not_active IP Right Cessation
- 2000-04-06 BR BR0009646-6A patent/BR0009646A/pt not_active Application Discontinuation
- 2000-04-06 PT PT05002951T patent/PT1535622E/pt unknown
- 2000-04-06 DK DK00107101T patent/DK1043026T3/da active
- 2000-04-06 DE DE60020444T patent/DE60020444T2/de not_active Expired - Lifetime
- 2000-04-06 DE DE60041290T patent/DE60041290D1/de not_active Expired - Lifetime
- 2000-04-06 CO CO00025236A patent/CO5170404A1/es not_active Application Discontinuation
- 2000-04-06 AT AT00107101T patent/ATE296639T1/de active
- 2000-04-06 JP JP2000105524A patent/JP2000319195A/ja not_active Withdrawn
- 2000-04-06 EP EP00107101A patent/EP1043026B1/en not_active Expired - Lifetime
- 2000-04-06 PT PT00107101T patent/PT1043026E/pt unknown
- 2000-04-06 WO PCT/US2000/009129 patent/WO2000061175A2/en active Application Filing
- 2000-04-06 DK DK05002951T patent/DK1535622T3/da active
- 2000-04-06 CN CN00808452A patent/CN1390132A/zh active Pending
- 2000-04-07 MY MYPI20001454A patent/MY126763A/en unknown
-
2001
- 2001-03-26 HK HK01102202A patent/HK1032349A1/xx not_active IP Right Cessation
- 2001-10-04 ZA ZA200108173A patent/ZA200108173B/en unknown
- 2001-10-05 NO NO20014852A patent/NO328111B1/no not_active IP Right Cessation
-
2005
- 2005-11-02 HK HK05109748.1A patent/HK1075416A1/xx not_active IP Right Cessation
-
2009
- 2009-03-24 CY CY20091100351T patent/CY1108922T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1173178T3 (da) | Præparat, der omfatter apomorfin og sildenafil, og anvendelse deraf til behandling af erektil dysfunktion | |
BR9911076A (pt) | Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica | |
HK1123741A1 (en) | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders (dextromethorphan)(quinidine) | |
BR0014912A (pt) | Tratamento de distúrbios do sono usando desloratadina | |
ES2267706T3 (es) | Agentes como la nicotinamida o cardr para el tratamiento de trastornos de la piel. | |
HUP0002755A2 (hu) | Eljárások szklerózis multiplexben szenvedő betegek kezelésére konszenzus interferonnal | |
BR0309837A (pt) | Forma de administração trans-epicutânea para tratamento da sìndrome das pernas inquietas | |
BR0115162A (pt) | Tratamentos antitumorais eficazes | |
PL1680128T3 (pl) | Heksafosforan mio-inozytolu do stosowania miejscowego | |
AR048318A1 (es) | Formulaciones de matriz orales que comprenden licarbazepina | |
BRPI0418157A (pt) | terapêutica de tumores alogênicos | |
BR0107960A (pt) | Tratamento de condições alérgicas e inflamatórias | |
TW200511999A (en) | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone | |
JP2003528919A5 (es) | ||
ATE297732T1 (de) | Kombinationstherapie zur behandlung von herzinsuffizienz | |
AR023398A1 (es) | Terapia para melanomas | |
CO5160259A1 (es) | Interferon alfa pegilado en la terapia contra el hiv | |
ECSP003419A (es) | Terapia para melanomas | |
ATE345805T1 (de) | Calciumtrifluoracetat mit zytotoxischer wirkung | |
NO20014851L (no) | Behandling av nyrecellekarsinom | |
AR109456A2 (es) | Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación | |
AR025711A1 (es) | El uso de la desloratadina para la preparacion de un medicamento para tratar y prevenir estados alergicos e inflamatorios | |
TR200000728T2 (tr) | Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı. | |
BR0009642A (pt) | Terapia de leucemia mielocìtica crÈnica | |
ECSP003373A (es) | Terapia contra el hiv |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |